Read by QxMD icon Read

Future Oncology

Yuchen Sun, Jizhao Wang, Yingchao Li, Shupei Pan, Tian Yang, Xuanzi Sun, Ya Wang, Xiaobo Shi, Xu Zhao, Xiaozhi Zhang
AIM: We aimed to investigate the effect of current treatment based on stage and histology type, which were important factors for treating esophageal cancer. METHODS: Log-rank test, COX and nomograms were used for survival analysis. DCA, C-index and calibration curves were used for validation. RESULTS: A total of 3224 patients were recruited. As for cT2-T4aM0 patients, chemotherapy and radiation prolonged overall survival (OS) for esophageal squamous cell carcinoma (ESCC) and chemotherapy improved OS for esophageal adenocarcinoma (EAC)...
September 20, 2018: Future Oncology
Xuefeng An, Hong Quan, Jinhui Lv, Lingyu Meng, Cheng Wang, Zuoren Yu, Jing Han
AIM: The present study aimed to identify microRNA (miRNA) that can be used for not only detecting early-stage breast cancer (BC) but also diagnosing atypical hyperplasia (AH). MATERIALS & METHODS: RT-qPCR detected the expression levels of miRNAs and receiver operating characteristic curves were constructed to evaluate sensitivity and specificity of the assay. RESULTS: miR-24 and miR-103a were expressed in an upward trend in serum of benign proliferative tumor subjects, while they were downregulated significantly in serum of AH (p < 0...
September 17, 2018: Future Oncology
Naoya Yamazaki, Yumi Oomuku, Izumi Mishiro, Junpei Soeda
AIM: Clinically managing skin toxicity associated with anti-EGFR antibody usage to treat colorectal cancer improves quality of life for colorectal cancer patients. This study assesses trends of pre-emptive skin treatments and their impact on subsequent dermatologist visits in Japanese colorectal cancer patients. PATIENTS & METHODS: Pre-emptive treatment status and dermatologist visit data were investigated for 9461 colorectal cancer patients who experienced anti-EGFR antibody treatment...
September 14, 2018: Future Oncology
Cong Liu, Wei Hu, Lin-Lin Li, Yu-Xuan Wang, Qun Zhou, Feng Zhang, Yi-Yan Song-Yang, Wei Zhu, Cheng-Chao Sun, De-Jia Li
miRNAs are a class of single-stranded noncoding RNAs, which have no coding potential, but modulate many molecular mechanisms including cancer pathogenesis. miRNAs participate in cell proliferation, differentiation, apoptosis, as well as carcinogenesis or cancer progression, and their involvement in lung cancer has been recently shown. They are suggested to have bidirectional functions on important cancer-related genes so as to enhance or attenuate tumor genesis. Epithelial-mesenchymal transition (EMT) is a fundamental process which contributes to integrity of organogenesis and tissue differentiation as well as tissue repair, organ fibrosis and the progression of carcinoma, and several miRNAs were suggested to form the network regulating EMT in lung cancer, among which, miR-200 family members (miR-200a, miR-200b, miR-200c, miR-429 and miR-141) play crucial roles in the suppression of EMT...
September 13, 2018: Future Oncology
Serena Merante, Virginia V Ferretti, Chiara Elena, Valeria Brazzelli, Roberta Zanotti, Iria Ner, Diomira Magliacane, Anna Belloni Fortina, Forer Ingeborg, Elide A Pastorello, Lisa Pieri, Cristina Papayannidis, Marina Mauro, Federica Grifoni, Roberto Minelli, Elena Guggiari, Elisa Difonzo, Monica Bocchia, Francesca Caroppo, Sergio Di Nuzzo, Elena Maria Elli, Michela Rondoni, Rachele Ciccocioppo, Michele Di Stefano, Grazia Bossi, Emanuela Boveri, Patrizia Bonadonna, Fiorina Giona, Peter Valent, Massimo Triggiani
AIM: We collected 'real-life' data on the management of patients with mastocytosis in the Italian Mastocytosis Registry. METHODS: Six hundred patients diagnosed with mastocytosis between 1974 and 2014 were included from 19 centers. RESULTS: Among adults (n = 401); 156 (38.9%) patients were diagnosed with systemic mastocytosis. In 212 adults, no bone marrow studies were performed resulting in a provisional diagnosis of mastocytosis of the skin...
September 12, 2018: Future Oncology
Francesca Maines, Ugo De Giorgi, Giuseppe Procopio, Gaetano Facchini, Lucia Fratino, Roberto Sabbatini, Donatello Gasparro, Umberto Basso, Claudia Mosillo, Enrico Campadelli, Francesco Massari, Teodoro Sava, Suzana Sirotova, Caterina Messina, Sarah Scagliarini, Vincenza Conteduca, Elena Verzoni, Sabrina Rossetti, Antonello Veccia, Stefania Kinspergher, Orazio Caffo
AIM: To collect efficacy and safety data of enzalutamide after docetaxel, we retrospectively evaluated the Italian Named Patient Program results. PATIENTS & METHODS: Two hundred and nine metastatic castration-resistant prostate cancer patients were enrolled. Median age was 73 years. Total 42.1% patients had pain, 14.4% had a performance status of two and 59.8% had a Gleason score ≥8. Total 31.1% had previously received ≥2 chemotherapies, 15.3 and 12% had been previously treated with abiraterone and cabazitaxel, respectively and 14...
September 12, 2018: Future Oncology
Christina Darden, Debanjali Mitra, David McSorley, Kimberly Davis, Juliet Band, Shrividya Iyer
AIM: To understand treatment satisfaction in patients with advanced or metastatic breast cancer receiving palbociclib plus an aromatase inhibitor or palbociclib plus fulvestrant in a real-world setting. PATIENTS & METHODS: We performed an observational, cross-sectional, web-based survey of 604 patients with self-reported hormone receptor-positive (HR+)/HER2-negative (HER2-) ABC/mBC in six countries. RESULTS: Overall, more than 96% of patients reported the benefits of their palbociclib combination therapy met or exceeded their expectations...
September 12, 2018: Future Oncology
Simone Ribero, Ottavia Malavenda, Paolo Fava, Chiara Astrua, Elena Marra, Simona Osella-Abate, Martina Sanlorenzo, Virginia Caliendo, Maria Teresa Fierro, Pietro Quaglino
AIM: A survival benefit was demonstrated by dabrafenib + trametinib for metastatic BRAF-mutated melanoma patients. Best response is a strong prognostic marker for survival. PATIENTS & METHODS: The specific features associated with complete response (CR) were evaluated. RESULTS: A total of 15/66 patients achieved CR. Median size of lesions was 3 cm (range: 0.5-10). Using that value as cut-off, the CR rate was 39.3% in patients with smaller lesions and 10...
September 10, 2018: Future Oncology
Savio George Barreto
No abstract text is available yet for this article.
September 7, 2018: Future Oncology
Sachin C Sarode, Nilesh Kumar Sharma, Gargi S Sarode, Pritish Nilendu, Shankargouda Patil
No abstract text is available yet for this article.
September 7, 2018: Future Oncology
Yasuo Hamamoto, Natalya Shin, Tomohiro Hoshino, Takanori Kanai
Immune-related gastrointestinal toxicities (irGI) are well-known adverse events (AEs) with immune checkpoint inhibitors. The aim of this review was to present clinical data from 82 cases to provide information to clinicians who face real-world challenges among their patients with irGI AEs. The findings of this review support the use of the current management guidelines. By analyzing the treatment courses and outcomes of all cases identified, our review recommends that recurrent cases be treated carefully regardless of the grade of diarrhea at the onset of events...
September 6, 2018: Future Oncology
Ajaz Bulbul, Emilio Araujo-Mino
Durvalumab consolidation after chemoradiation has been a giant leap in the treatment of stage III non-small-cell lung cancer with an unprecedented 16.8-month median progression-free survival. PACIFIC trial is a new foray into chemoimmunotherapy trials where we apply our knowledge of 'immunogenic cell death' and 'Abscopal' effect of radiation in the clinic. Our understanding of immunotherapy after chemoradiation treatment and application of immunogenic cell death biomarkers in future trials may be the approach we need to maximize benefit of these treatments in the appropriate patients...
September 3, 2018: Future Oncology
Nancy Tray, Sylvia Adams, Francisco J Esteva
Triple negative breast cancer (TNBC) is a heterogeneous disease that comprises 15-20% of all breast cancers and is more frequently seen in younger women, African-Americans, and BRCA1 expression. Advanced TNBC carries aggressive features and is associated with overall poor outcomes. Unfortunately, there are no targeted therapies available for non-BRCA associated TNBC, which remains a high unmet therapeutic need. One emerging treatment modality includes antibody-drug conjugates which are highly selective monoclonal antibodies conjugated to cytotoxic agents, designed to deliver cytotoxic drugs to antigen-expressing tumor cells...
September 3, 2018: Future Oncology
Mariana Brandão, Noam Pondé, Martine Piccart-Gebhart
The number of breast cancer (BC) cases is growing worldwide, being most frequently diagnosed in the early-setting. Mammaprint™ is a 70-gene-expression signature, originally designed for selecting early BC patients with low risk of developing metastasis, so that they could be spared adjuvant chemotherapy. Its use as a prognostic biomarker has been extensively validated, both retrospectively and prospectively. However, its value as a predictive tool and as a clinically useful tool remains controversial. This review will describe how the test works, its application in the clinic and its limitations...
August 29, 2018: Future Oncology
Wei Wang, Yukai He, Sha Wu
No abstract text is available yet for this article.
August 24, 2018: Future Oncology
Vincenzo Di Nunno, Alessia Cimadamore, Matteo Santoni, Marina Scarpelli, Michelangelo Fiorentino, Chiara Ciccarese, Roberto Iacovelli, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Rodolfo Montironi
No abstract text is available yet for this article.
August 24, 2018: Future Oncology
Lei Zhang, Qing-Gen Chen, Shu-Qi Li, Jing Zhang, Qing-Hua Min, Qiu-Fang Gao, Fan Sun, Yu-Huan Jiang, Xiao-Zhong Wang, Hou-Qun Ying
AIM: To investigate prognostic value of preoperative inflammatory biomarkers in hepatocellular carcinoma (HCC). PATIENTS & METHODS: Preoperative circulating fibrinogen, prealbumin, fibrinogen to prealbumin ratio (FPR), neutrophil to lymphocyte ratio, derived neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio, platelet to lymphocyte ratio were detected and calculated in 230 HCC patients. X-tile software, Kaplan-Meier curve, Cox regression, time-dependent receiver-operating characteristic were used to explored prognostic roles of them in HCC...
August 24, 2018: Future Oncology
Sarah Chehab, Elyse Hall Panjic, Charise Gleason, Sagar Lonial, Ajay K Nooka
Daratumumab gained initial US FDA approval as fourth-line therapy among relapsed and/or refractory multiple myeloma (RRMM) patients who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and immunomodulatory drug (IMiD), or who are double refractory to a PI and an IMiD. Further combination trials of daratumumab led to FDA approvals in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone for multiple myeloma patients who have received at least one prior therapy...
August 23, 2018: Future Oncology
Karla R Bowles, Debora Mancini-DiNardo, Bradford Coffee, Hannah C Cox, Yaping Qian, Maria Elias, Nanda Singh, Thaddeus Judkins, Benoît Leclair, Benjamin B Roa
Expanded genetic test utilization to guide cancer management has driven the development of larger gene panels and greater diversity in the patient population pursuing testing, resulting in increased identification of atypical or technically challenging genetic findings. To ensure appropriate patient care, it is critical that genetic tests adequately identify and characterize these findings. We describe genetic testing challenges frequently encountered by our laboratory and the methodologies we employ to improve test accuracy for the identification and characterization of atypical genetic findings...
August 16, 2018: Future Oncology
Michael Leisch, Alexander Egle, Richard Greil
Plitidepsin is a marine-derived anticancer compound isolated from the Mediterranean tunicate Applidium albicans. It exerts pleiotropic effects on cancer cells, most likely by binding to the eukaryotic translation eEF1A2. This ultimately leads to cell-cycle arrest, growth inhibition and induction of apoptosis via multiple pathway alterations. Recently, a Phase III randomized trial in patients with relapsed/refractory multiple myeloma reported outcomes for plitidepsin plus dexamethasone compared with dexamethasone...
August 16, 2018: Future Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"